A population-based study of infection-related hospital mortality in patients with dermatomyositis/polymyositis

Arthritis Care and Research

Volumn 67, Issue 5, 2015, Pages 673-680

  Murray, Sara G ^a   Schmajuk, Gabriela ^b   Trupin, Laura ^a   Lawson, Erica ^a   Cascino, Matthew ^a   Barton, Jennifer ^a,c   Margaretten, Mary ^a,c   Katz, Patricia P ^a,d   Yelin, Edward H ^a,d   Yazdany, Jinoos ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; ARTICLE; BACTEREMIA; CAUCASIAN; COMORBIDITY; CONTROLLED STUDY; DERMATOMYOSITIS; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MYCOSIS; OPPORTUNISTIC INFECTION; PNEUMONIA; POLYMYOSITIS; PREVALENCE; RISK FACTOR; AGED; BACTERIAL INFECTIONS; CAUSE OF DEATH; EPIDEMIOLOGY; FACTUAL DATABASE; MEDICAL RECORD; MYCOSES; ODDS RATIO; OPPORTUNISTIC INFECTIONS; STATISTICAL MODEL; TIME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BACTERIAL INFECTIONS; CAUSE OF DEATH; DATABASES, FACTUAL; DERMATOMYOSITIS; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYCOSES; ODDS RATIO; OPPORTUNISTIC INFECTIONS; PATIENT DISCHARGE SUMMARIES; POLYMYOSITIS; PREVALENCE; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84928547239     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22501     Document Type: Article

References (28)

1. Mammen AL., Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184: 134-53.
2. Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol 2001; 28: 2230-7.
3. Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC., Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther 2012; 14: R22.
4. Taborda AL, Azevedo P, Isenberg DA., Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy: a long-term follow up. Clin Exp Rheumatol 2014; 32: 188-93.
5. Airio A, Kautiainen H, Hakala M., Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006; 25: 234-9.
6. Limaye V, Hakendorf P, Woodman RJ, Blumbergs P, Roberts-Thomson P., Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J 2012; 42: 191-8.
7. Linos E, Fiorentino D, Lingala B, Krishnan E, Chung L., Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Arthritis Res Ther 2013; 15: R7.
8. Marie I, Menard JF, Hachulla E, Cherin P, Benveniste O, Tiev K, et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum 2011; 41: 48-60.
9. Chen IJ, Tsai WP, Wu YJ, Luo SF, Ho HH, Liou LB, et al. Infections in polymyositis and dermatomyositis: analysis of 192 cases. Rheumatology (Oxford) 2010; 49: 2429-37.
10. Bernatsky S, Linehan T, Hanly JG., The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases. J Rheumatol 2011; 38: 1612-6.
11. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-9.
12. Jones N, Schneider G, Kachroo S, Rotella P, Avetisyan R, Reynolds MW., A systematic review of validated methods for identifying pulmonary fibrosis and interstitial lung disease using administrative and claims data. Pharmacoepidemiol Drug Saf 2012; 21: 256-60.
13. Schneeweiss S, Robicsek A, Scranton R, Zuckerman D, Solomon DH., Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol 2007; 60: 397-409.
14. Barber C, Lacaille D, Fortin PR., Systematic review of validation studies of the use of administrative data to identify serious infections. Arthritis Care Res (Hoboken) 2013; 65: 1343-57.
15. Grijalva CG, Chung CP, Stein CM, Gideon PS, Dyer SM, Mitchel EF Jr, et al. Computerized definitions showed high positive predictive values for identifying hospitalizations for congestive heart failure and selected infections in Medicaid enrollees with rheumatoid arthritis. Pharmacoepidemiol Drug Saf 2008; 17: 890-5.
16. McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48: 1364-71.
17. Drahos J, Vanwormer JJ, Greenlee RT, Landgren O, Koshiol J., Accuracy of ICD-9-CM codes in identifying infections of pneumonia and herpes simplex virus in administrative data. Ann Epidemiol 2013; 23: 291-3.
18. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL., Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007; 35: 1244-50.
19. Marie I, Hachulla E, Cherin P, Hellot MF, Herson S, Levesque H, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005; 53: 155-65.
20. Fiske CT, Griffin MR, Mitchel E, Sterling TR, Grijalva CG., Accuracy of pharmacy and coded-diagnosis information in identifying tuberculosis in patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf 2012; 21: 666-9.
21. Trepka MJ, Beyer TO, Proctor ME, Davis JP., An evaluation of the completeness of tuberculosis case reporting using hospital billing and laboratory data, Wisconsin, 1995. Ann Epidemiol 1999; 9: 419-23.
22. Winthrop KL, Baxter R, Liu L, McFarland B, Austin D, Varley C, et al. The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy. Pharmacoepidemiol Drug Saf 2011; 20: 229-35.
23. Smoyer-Tomic KE, Amato AA, Fernandes AW., Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord 2012; 13: 103.
24. Golestanian E, Scruggs JE, Gangnon RE, Mak RP, Wood KE., Effect of interhospital transfer on resource utilization and outcomes at a tertiary care referral center. Crit Care Med 2007; 35: 1470-6.
25. Sharp AL, Choi H, Hayward RA., Don't get sick on the weekend: an evaluation of the weekend effect on mortality for patients visiting US EDs. Am J Emerg Med 2013; 31: 835-7.
26. Ricciardi R, Nelson J, Roberts PL, Marcello PW, Read TE, Schoetz DJ., Is the presence of medical trainees associated with increased mortality with weekend admission? BMC Med Educ 2014; 14: 4.
27. Patkar NM, Curtis JR, Teng GG, Allison JJ, Saag M, Martin C, et al. Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol 2009; 62: 321-7.
28. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61: 816-9.